(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone has been researched along with jwh-133 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chavatte, P; Depreux, P; Farce, A; Goossens, JF; Hénichart, JP; Lambert, DM; Millet, R; Muccioli, GG; Poupaert, JH; Stern, E | 1 |
| Benetti, V; Castelli, MP; Cavallini, T; Ferrarini, PL; Lazzarotti, S; Manera, C; Martinelli, A; Pibiri, F; Saccomanni, G; Tuccinardi, T; Vannacci, A | 1 |
| Bosier, B; Depreux, P; Goossens, JF; Hamtiaux, L; Hénichart, JP; Lambert, DM; Millet, R; Muccioli, GG; Poupaert, JH; Stern, E | 1 |
| Brogi, S; Corelli, F; Di Marzo, V; Ligresti, A; Mugnaini, C; Pasquini, S; Tafi, A | 1 |
| Buzard, DJ; Han, S; Jones, RM; Thatte, J | 1 |
| Appendino, G; Caprioglio, D; Chicca, A; Gertsch, J; Minassi, A; Petrucci, V; Taglialatela-Scafati, O | 1 |
| Carrillo-Salinas, FJ; Fernández-Ruiz, J; Franco, R; Gómez-Cañas, M; Goya, P; Guaza, C; Hurst, DP; Jagerovic, N; Lagartera, L; Morales, P; Navarro, G; Pazos, R; Reggio, PH | 1 |
| Barczyk, A; Baudelet, D; Body-Malapel, M; Carato, P; Djouina, M; Heloire, VM; Leleu-Chavain, N; Millet, R; Renault, N; Rocha, DE | 1 |
| Campillo, NE; de Ceballos, ML; Girón, R; González-Naranjo, P; Martín-Fontelles, MI; Martin-Requero, A; Páez, JA; Pérez, C; Pérez-Macias, N; Roca, C; Sánchez-Robles, E; Vaca, G | 1 |
| Arena, C; Bertini, S; Carpi, S; Cervetto, C; Chicca, A; Chicca, S; D'Andrea, F; Di Cesare Mannelli, L; Digiacomo, M; Gado, F; Gertsch, J; Ghelardini, C; Lucarini, E; Macchia, M; Manera, C; Marcoli, M; Nieri, P; Poli, G; Polini, B; Reynoso-Moreno, I; Tuccinardi, T; Vallini, E | 1 |
1 review(s) available for (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and jwh-133
| Article | Year |
|---|---|
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Topics: Animals; Drug Design; Humans; Ligands; Models, Molecular; Molecular Conformation; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Substrate Specificity | 2013 |
9 other study(ies) available for (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and jwh-133
| Article | Year |
|---|---|
Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
Topics: Crystallography, X-Ray; Humans; Models, Molecular; Molecular Structure; Quinolones; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2006 |
Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
Topics: Amides; Animals; Basophils; Brain; Drug Design; Guanosine 5'-O-(3-Thiotriphosphate); Humans; In Vitro Techniques; Ligands; Male; Mice; Mice, Inbred DBA; Models, Molecular; Naphthyridines; Phosphoric Diester Hydrolases; Pyrophosphatases; Quinolines; Radioligand Assay; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Thermodynamics | 2006 |
Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
Topics: Amides; Animals; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Drug Inverse Agonism; Humans; Ligands; Quinolines; Radioligand Assay; Receptor, Cannabinoid, CB2; Stereoisomerism; Structure-Activity Relationship | 2007 |
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
Topics: Computer Simulation; Drug Design; Humans; Ligands; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship; Quinolones; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Recombinant Proteins; Stereoisomerism | 2011 |
Functionalization of β-caryophyllene generates novel polypharmacology in the endocannabinoid system.
Topics: Amidohydrolases; Animals; Anti-Inflammatory Agents, Non-Steroidal; CHO Cells; Cricetulus; Cyclooxygenase 2 Inhibitors; Endocannabinoids; Humans; Polycyclic Sesquiterpenes; Polypharmacology; Receptor, Cannabinoid, CB2; Sesquiterpenes; Syzygium | 2014 |
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.
Topics: Dose-Response Relationship, Drug; HEK293 Cells; Humans; Models, Molecular; Molecular Structure; Multiple Sclerosis; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2016 |
Benzo[d]thiazol-2(3H)-ones as new potent selective CB
Topics: Anti-Inflammatory Agents; Benzothiazoles; Cannabinoid Receptor Agonists; Colon; Humans; Inflammation; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2019 |
Indazolylketones as new multitarget cannabinoid drugs.
Topics: Aspartic Acid Endopeptidases; Butyrylcholinesterase; Cannabinoids; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Drug Design; Humans; Indazoles; Ketones; Neurons; Receptor, Cannabinoid, CB2 | 2019 |
The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Female; Ligands; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Molecular Structure; Multiple Sclerosis; Protein Binding; Pyridones; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2020 |